1. Home
  2. EYPT vs DLX Comparison

EYPT vs DLX Comparison

Compare EYPT & DLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • DLX
  • Stock Information
  • Founded
  • EYPT 1987
  • DLX 1915
  • Country
  • EYPT United States
  • DLX United States
  • Employees
  • EYPT N/A
  • DLX N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • DLX Advertising
  • Sector
  • EYPT Industrials
  • DLX Consumer Discretionary
  • Exchange
  • EYPT Nasdaq
  • DLX Nasdaq
  • Market Cap
  • EYPT 579.4M
  • DLX 655.1M
  • IPO Year
  • EYPT 2005
  • DLX N/A
  • Fundamental
  • Price
  • EYPT $9.65
  • DLX $16.35
  • Analyst Decision
  • EYPT Strong Buy
  • DLX Strong Buy
  • Analyst Count
  • EYPT 8
  • DLX 1
  • Target Price
  • EYPT $24.75
  • DLX $23.00
  • AVG Volume (30 Days)
  • EYPT 841.7K
  • DLX 413.1K
  • Earning Date
  • EYPT 08-06-2025
  • DLX 07-30-2025
  • Dividend Yield
  • EYPT N/A
  • DLX 7.36%
  • EPS Growth
  • EYPT N/A
  • DLX 61.76
  • EPS
  • EYPT N/A
  • DLX 1.24
  • Revenue
  • EYPT $56,042,000.00
  • DLX $2,123,277,000.00
  • Revenue This Year
  • EYPT N/A
  • DLX $0.67
  • Revenue Next Year
  • EYPT N/A
  • DLX $1.08
  • P/E Ratio
  • EYPT N/A
  • DLX $13.09
  • Revenue Growth
  • EYPT 12.04
  • DLX N/A
  • 52 Week Low
  • EYPT $3.91
  • DLX $13.61
  • 52 Week High
  • EYPT $13.99
  • DLX $24.87
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 61.83
  • DLX 65.43
  • Support Level
  • EYPT $8.96
  • DLX $15.59
  • Resistance Level
  • EYPT $10.77
  • DLX $16.74
  • Average True Range (ATR)
  • EYPT 0.74
  • DLX 0.39
  • MACD
  • EYPT -0.02
  • DLX 0.15
  • Stochastic Oscillator
  • EYPT 60.25
  • DLX 81.63

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About DLX Deluxe Corporation

Deluxe Corporation is principally a payments and data company. Its reportable segments are; Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services as well as financial institution profitability reporting and business incorporation services.

Share on Social Networks: